Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.verified

ESPR

Price:

$2.99

Market Cap:

$509.55M

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2013-06-26

Stock Exchange

NASDAQ

Ticker

ESPR

The PE Ratio as of June 2024 (TTM) for Esperion Therapeutics, Inc. (ESPR) is -3.32

According to Esperion Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.32. This represents a change of 1.25% compared to the average of -0.25 of the last 4 quarters.

Esperion Therapeutics, Inc. (ESPR) Historical PE Ratio (quarterly & annually)

How has ESPR PE Ratio performed in the past?

The mean historical PE Ratio of Esperion Therapeutics, Inc. over the last ten years is -6.98. The current -3.32 PE Ratio has changed 4.65% with respect to the historical average. Over the past ten years (40 quarters), ESPR's PE Ratio was at its highest in in the March 2019 quarter at 3.09. The PE Ratio was at its lowest in in the March 2015 quarter at -41.57.

Quarterly (TTM)
Annual

Average

-6.98

Median

-5.20

Minimum

-18.20

Maximum

-0.45

Esperion Therapeutics, Inc. (ESPR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Esperion Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 338.30%

Maximum Annual PE Ratio = -0.45

Minimum Annual Increase = -89.45%

Minimum Annual PE Ratio = -18.20

Quarterly (TTM)
Annual
YearPE RatioChange
2023-1.472.50%
2022-1.44217.13%
2021-0.45-89.45%
2020-4.30-70.99%
2019-14.82142.97%
2018-6.10-35.37%
2017-9.44150.67%
2016-3.76-61.76%
2015-9.85-45.91%
2014-18.20338.30%

Esperion Therapeutics, Inc. (ESPR) Average PE Ratio

How has ESPR PE Ratio performed in the past?

The current PE Ratio of Esperion Therapeutics, Inc. (ESPR) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-1.12

5-year avg

-4.50

10-year avg

-6.98

Esperion Therapeutics, Inc. (ESPR) PE Ratio vs. Peers

How is ESPR’s PE Ratio compared to its peers?

Esperion Therapeutics, Inc.’s PE Ratio is greater than Elanco Animal Health Incorporated (-6.83), less than SIGA Technologies, Inc. (5.98), greater than Indivior PLC (-52.20), greater than Catalent, Inc. (-9.11), less than Eagle Pharmaceuticals, Inc. (2.64), less than ANI Pharmaceuticals, Inc. (33.65), less than Phibro Animal Health Corporation (52.93), greater than Deciphera Pharmaceuticals, Inc. (-11.74), less than Prestige Consumer Healthcare Inc. (15.29), less than Collegium Pharmaceutical, Inc. (11.00), less than Pacira BioSciences, Inc. (18.56), greater than Intra-Cellular Therapies, Inc. (-59.22), less than Alkermes plc (9.47), less than Neurocrine Biosciences, Inc. (36.56), less than Ironwood Pharmaceuticals, Inc. (-0.87), greater than Avadel Pharmaceuticals plc (-9.24), less than Lifecore Biomedical, Inc. (-3.06), greater than Rockwell Medical, Inc. (-6.44), less than Kamada Ltd. (23.48), less than Agile Therapeutics, Inc. (-0.21),

Build a custom stock screener for Esperion Therapeutics, Inc. (ESPR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Esperion Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Esperion Therapeutics, Inc. (ESPR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Esperion Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Esperion Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Esperion Therapeutics, Inc. (ESPR)?

What is the highest PE Ratio for Esperion Therapeutics, Inc. (ESPR)?

What is the 3-year average PE Ratio for Esperion Therapeutics, Inc. (ESPR)?

What is the 5-year average PE Ratio for Esperion Therapeutics, Inc. (ESPR)?

How does the current PE Ratio for Esperion Therapeutics, Inc. (ESPR) compare to its historical average?